查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1461371

白塞氏症治疗药物市场：现况分析与预测（2023-2030）

Behcet's Disease Therapeutics Market: Current Analysis and Forecast (2023-2030)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 137 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

由于白塞氏症在全球的盛行率不断增加，白塞氏症治疗药物市场预计将以约 5.1% 的速度稳定成长。 例如，根据国家罕见疾病组织的数据，白塞氏症最常见于中东和亚洲。 土耳其的盛行率最高，日本、韩国、中国、伊朗和沙乌地阿拉伯的盛行率也很高。 它是日本第一大失明原因。 在预测期内，有几个因素正在推动市场成长，包括寻找有效治疗方法的临床试验数量的增加以及医疗保健行业投资的增加。 除此之外，白塞氏症药物诊断的加速增加了对有效治疗方法的需求，这也正在稳步推动白塞氏症药物市场。

依治疗，市场分为皮质类固醇、免疫抑制剂等。 由于严重白塞氏症患者的增加，免疫抑制剂领域在 2022 年占市场主导地位。 免疫抑制剂是白塞氏症治疗方案的重要组成部分，适用于单独使用皮质类固醇治疗效果不佳或需要长期治疗以防止病情发作的患者。 这些药物的作用是抑制导致白塞氏症发炎的过度免疫反应。 因此，2022年，免疫抑制剂领域将在治疗药物中占有较大的市场占有率。

依给药途径，市场分为口服製剂、注射製剂等。 由于临床试验数量不断增加，预计注射剂市场在预测期内将以高复合年增长率成长。 例如，2023年1月，索哈格大学在索哈格大学医院启动了一项临床试验，以评估阿达木单抗治疗成人患者白塞氏症相关葡萄膜炎的安全性和有效性。 注射剂用于治疗白塞氏症，特别是对于无法耐受需要快速起效或高剂量的药物或无法耐受口服药物的患者。 透过注射给药可以将药物直接输送到血流中，确保全身份布。 治疗行业的成长是由技术创新、疾病盛行率增加、医疗保健服务的改善以及对早期干预和联合治疗方法的日益重视所推动的。 因此，在给药途径中，注射剂领域预计在预测期内将出现较高的复合年增长率。

依分销管道划分，市场分为医院药局、零售药局等。 2022年，医院药局产业将主导市场。 医院药局透过确保用于治疗白塞氏症的药物的可用性、适当储存、准备和配发，在白塞氏症的治疗中发挥重要作用。 医院药房满足白塞氏症住院患者和门诊患者的需求，在整个治疗过程中提供全面的药物和支持。 除此之外，医院数量的增加也支持了该行业的成长。 例如，根据美国医院协会的数据，2022 年 10 月，美国约有 6,093 家医院，由非营利组织以及州和地方政府营运的社区医院组成。 因此，2022年，医院在白塞氏症治疗药物市场中占有很大占有率。

为了更瞭解白塞病药物的市场介绍，将市场分为北美（美国、加拿大等北美地区）、欧洲（德国、英国、法国、西班牙、义大利等欧洲地区）和亚太地区（根据世界其他地区（中国、日本、印度、亚太其他地区）和世界其他地区的全球影响力进行分析。 预计在预测期内，亚太地区的全球白塞氏症治疗市场将以高复合年增长率成长。 在预测期内，有几个因素正在推动市场成长，包括进行的临床试验数量的快速增加、可及性的提高以及医疗保健成本的多样化。 例如，2023年12月，中国Ganzhou Hemay Pharmaceutical Co., Ltd.启动了一项临床试验，研究Hemay005片剂对白塞氏症患者的疗效和安全性。 此外，白塞氏症患者数量的增加也对市场成长产生正面影响。 该地区是主要罕见疾病宣传项目和产品促销活动的所在地。 因此，预计亚太地区在预测期内的复合年增长率将更高。

该市场营运的主要公司包括AbbVie, Eisai, Inos, Amgen, Mitsubishi Chemical Group, Bristol-Myers Squibb, Sanguin Biosciences, Takeda Pharmaceutical, Celltrion, Cardinal Health。

目录

第一章市场介绍

  • 市场定义
  • 主要目标
  • 利害关係人
  • 限制

第二章研究方法或前提

  • 调查过程
  • 调查方法
  • 受访者简介

第三章市场总结

第 4 章执行摘要

第五章 COVID-19 对白塞氏症治疗药物市场的影响

第六章白塞氏症治疗药物市场收入，2020-2030

第七章依处理法进行市场分析

  • 皮质类固醇
  • 免疫抑制剂
  • 其他

第 8 章依给药途径进行的市场分析

  • 口头
  • 注射
  • 其他

第 9 章依通路划分的市场分析

  • 医院药房
  • 零售药局
  • 其他

第10章区域市场分析

  • 北美
    • 美国
    • 加拿大
    • 其他北美地区
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区

第11章白塞氏症药物市场动态

  • 市场驱动因素
  • 市场课题
  • 影响分析

第十二章白塞氏症治疗药物市场机会

第十三章白塞氏症治疗药物市场趋势

第十四章供需分析

  • 需求方分析
  • 供给面分析

第 15 章价值链分析

第16章比赛场景

  • 竞争状况
    • 波特五力分析

第十七章公司简介

  • AbbVie Inc.
  • Eisai Co., Ltd.
  • Ainos Inc.
  • Amgen Inc.
  • Mitsubishi Chemical Group Corporation
  • Bristol-Myers Squibb Company
  • Sanguine Biosciences
  • Takeda Pharmaceutical Company Limited
  • CELLTRION INC.
  • Cardinal Health

第 18 条免责声明

简介目录
Product Code: UMHE212676

Behcet's disease is a rare autoimmune disorder characterized by inflammation of blood vessels throughout the body, resulting in a wide range of symptoms. These may include recurrent oral ulcers, genital ulcers, skin lesions, eye inflammation, and joint pain. It can affect the gastrointestinal tract, central nervous system, and blood vessels. It's believed to involve a combination of genetic predisposition and environmental factors, such as infections or autoimmune triggers. A rising number of clinical trials and technological advancements are leading to the market's growth. Several other factors, such as rising research & development activities, rising healthcare expenditure, rising regulatory support, and a surge in government collaborations & partnerships are driving the behcet's disease therapeutics market globally.

The Behcet's Disease Therapeutics Market is expected to grow at a steady rate of around 5.1% owing to the growing prevalence of behcet's disease globally. For instance, according to the National Organization for Rare Disorders, Inc., behcet's disease occurs most frequently in the Middle East and Asia. Turkey has the highest prevalence rate; Japan, Korea, China, Iran, and Saudi Arabia also have high prevalence rates. The disorder is the leading cause of blindness in Japan. Several factors, including a rising number of clinical trials to find effective treatment, and rising investments in healthcare departments are driving the market's growth during the forecast period. Apart from this, accelerated diagnosis of behcet's disease therapeutics has resulted in higher demand for effective treatment procedures which are also driving this market of behcet's disease therapeutics at a steady rate.

Based on the treatment, the market is segmented into corticosteroids, immunosuppressive agents, and others. The immunosuppressive agents segment dominated the market in the year 2022 owing to the rising cases of severe Behcet's disease. Immunosuppressive agents are an important component of the treatment regimen for Behcet's disease, for patients who do not respond adequately to corticosteroids alone or who require long-term management to prevent recurrent flares. These medications work by suppressing the overactive immune response responsible for inflammation in Behcet's disease. Thus, among the treatments, the immunosuppressive agents segment held a significant market share in 2022.

Based on the route of administration, the market is segmented into oral, injectables, and others. The injectables segment is expected to grow with a high CAGR during the forecast period because of the rising number of clinical trials. For instance, in January 2023, Sohag University initiated a clinical trial to assess the safety and efficacy of adalimumab therapy for the treatment of Behcet's disease-related uveitis in adult patients at Sohag University Hospital. An injectable route of administration is utilized in Behcet's disease treatment, particularly for medications that require rapid onset of action, higher doses, or for individuals who cannot tolerate oral medications. Injectable administration allows for direct delivery of medications into the bloodstream, ensuring systemic distribution throughout the body. The growth of the treatment segment is driven by technological innovation, increasing disease prevalence, improved access to healthcare services, and a growing emphasis on early intervention and combination therapy approaches. Thus, the injectables segment among routes of administration is expected to witness a higher CAGR during the forecast period.

Based on distribution channel, the market is categorized into hospitals pharmacies, retail pharmacies, and others. The hospital pharmacy segment dominated the market in the year 2022. Hospital pharmacies play a crucial role in Behcet's disease treatment by ensuring the availability, proper storage, preparation, and dispensing of medications used in the management of this condition. Hospital pharmacies cater to the needs of both inpatients and outpatients receiving treatment for Behcet's disease, providing comprehensive pharmaceutical care and support throughout the treatment process. Apart from this, the growing number of hospital set-ups is also propelling segmental growth. For instance, according to the American Hospital Association, there were about 6,093 hospitals in the U.S. in October 2022, which comprises community hospitals run by non-profit organizations as well as by state and local governments. Thus, hospitals held a significant share of the behcet's disease therapeutics market in 2022.

For a better understanding of the market adoption of behcet's disease therapeutics, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is expected to grow with a high CAGR in the global behcet's disease therapeutics market in the forecast period. Several factors such as a surge in the number of clinical trials being performed, enhanced accessibility, and diversified healthcare costs are driving the market's growth during the forecast period. For instance, in December 2023, China-based Ganzhou Hemay Pharmaceutical Co., Ltd. initiated a clinical trial to study the efficacy and safety of Hemay005 tablets in patients with behcet's disease. Further, the increase in incidences of behcet's disease is also having a positive impact on the market's growth. There have been major awareness programs regarding rare diseases and product launches in the region. Thus, APAC is expected to witness a higher CAGR during the forecast period.

Some of the major players operating in the market include AbbVie Inc.; Eisai Co., Ltd.; Ainos Inc.; Amgen Inc.; Mitsubishi Chemical Group Corporation; Bristol-Myers Squibb Company; Sanguine Biosciences; Takeda Pharmaceutical Company Limited; CELLTRION INC.; Cardinal Health.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

  • 1.1.Market Definitions
  • 1.2.Main Objective
  • 1.3.Stakeholders
  • 1.4.Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1.Research Process of the Behcet's Disease Therapeutics Market
  • 2.2.Research Methodology of the Behcet's Disease Therapeutics Market
  • 2.3.Respondent Profile

3.MARKET SYNOPSIS

4.EXECUTIVE SUMMARY

5.IMPACT OF COVID-19 ON THE BEHCET'S DISEASE THERAPEUTICS MARKET

6.BEHCET'S DISEASE THERAPEUTICS MARKET REVENUE (USD BN), 2020-2030F

7.MARKET INSIGHTS BY TREATMENT

  • 7.1.Corticosteroids
  • 7.2.Immunosuppressive Agents
  • 7.3.Others

8.MARKET INSIGHTS BY ROUTE OF ADMINISTRATION

  • 8.1.Oral
  • 8.2.Injectables
  • 8.3.Others

9.MARKET INSIGHTS BY DISTRIBUTION CHANNEL

  • 9.1.Hospitals Pharmacies
  • 9.2.Retail Pharmacies
  • 9.3.Others

10.MARKET INSIGHTS BY REGION

  • 10.1.North America
    • 10.1.1.U.S.
    • 10.1.2.Canada
    • 10.1.3.Rest of North America
  • 10.2.Europe
    • 10.2.1.Germany
    • 10.2.2.U.K.
    • 10.2.3.France
    • 10.2.4.Italy
    • 10.2.5.Spain
    • 10.2.6.Rest of Europe
  • 10.3.Asia-Pacific
    • 10.3.1.China
    • 10.3.2.Japan
    • 10.3.3.India
    • 10.3.4.Rest of Asia-Pacific
  • 10.4.Rest of World

11.BEHCET'S DISEASE THERAPEUTICS MARKET DYNAMICS

  • 11.1.Market Drivers
  • 11.2.Market Challenges
  • 11.3.Impact Analysis

12.BEHCET'S DISEASE THERAPEUTICS MARKET OPPORTUNITIES

13.BEHCET'S DISEASE THERAPEUTICS MARKET TRENDS

14.DEMAND AND SUPPLY-SIDE ANALYSIS

  • 14.1.Demand Side Analysis
  • 14.2.Supply Side Analysis

15.VALUE CHAIN ANALYSIS

16.COMPETITIVE SCENARIO

  • 16.1.Competitive Landscape
    • 16.1.1.Porters Fiver Forces Analysis

17.COMPANY PROFILED

  • 17.1.AbbVie Inc.
  • 17.2.Eisai Co., Ltd.
  • 17.3.Ainos Inc.
  • 17.4.Amgen Inc.
  • 17.5.Mitsubishi Chemical Group Corporation
  • 17.6.Bristol-Myers Squibb Company
  • 17.7.Sanguine Biosciences
  • 17.8.Takeda Pharmaceutical Company Limited
  • 17.9.CELLTRION INC.
  • 17.10.Cardinal Health

18.DISCLAIMER